
Impaired glucose tolerance (IGT) and type 2 diabetes mellitus (T2DM) are distinct glycemic states, but their associated molecular profiles remain incompletely characterized. Urine is collected noninvasively and may capture systemic molecular changes relevant to biomarker discovery. We compared urinary proteome profiles across normal glucose tolerance (NGT), IGT, and T2DM in a cross-sectional study and developed candidate multiprotein classifiers. In this cross-sectional study, urine samples from 34 NGT individuals, 15 patients with IGT, and 17 patients with T2DM were analyzed by data-independent acquisition (DIA) liquid chromatography-tandem mass spectrometry (LC-MS/MS). Candidate proteins were screened using an exploratory dual threshold of fold change (FC) ≥ 1.5 or ≤ 0.67 and an unadjusted two-tailed t-test p < 0.05. Functional enrichment used DAVID, and individual-protein performance was assessed by receiver operating characteristic (ROC) curve analysis. Multiprotein logistic-regression classifiers were evaluated by fully nested cross-validation. Within each outer leave-one-out cross-validation (LOOCV) training set, the analysis repeated differential-protein selection, AUC ranking, combination selection, scaling, and model fitting. A total of 3,569 urinary proteins were identified. The exploratory screening criteria yielded candidate lists of 84 proteins for IGT versus NGT, 261 for T2DM versus NGT, and 128 for T2DM versus IGT. These proteins included C-reactive protein (CRP), catalase (CAT), and toll-like receptor 3 (TLR3), and were enriched in pathways related to advanced glycation end product-receptor for advanced glycation end product (AGE-RAGE) signaling, oxidative stress responses, and angiogenesis. The highest AUCs for individual proteins were observed for HLA-C in IGT versus NGT (AUC = 0.806), PRAP1 in T2DM versus NGT (AUC = 0.829), and APOC2 in T2DM versus IGT (AUC = 0.827). Fully nested cross-validation yielded outer LOOCV AUCs of 0.590 (95
The AllPrep DNA/RNA/Protein kit enables the simultaneous extraction of DNA, RNA and protein from a single biological sample, facilitating downstream analysis. This strategy is crucial when samples are limited and eliminates the need to split material for separate extractions, which is currently the default approach. Despite its widespread use, the compatibility of this workflow with unbiased, global proteomic analyses remains uncharacterized. We systematically compared precipitation-based and non-precipitation-based protein cleanup methods to assess the suitability of this strategy for high-throughput proteomic applications. Precipitation-based protein cleanup typically performed in the AllPrep workflow was compared to non-precipitation-based methods including single-pot, solid-phase–enhanced sample preparation (SP3) protocol. The SP3-based workflow was comparable to precipitation-based methods in terms of protein and peptide identifications along with the missed cleavages and peptide length distribution. Further optimization of the conditions enabling protein binding to SP3 beads showed minimal impact on performance of the SP3 workflow. Importantly, this workflow was automated using the KingFisher Apex liquid handling platform to obtain robust and reproducible performance. To demonstrate the utility of this workflow, we applied it to investigate proteomic alterations in a multiple myeloma cell line following treatment with the immunomodulatory drug, pomalidomide. When coupled with diaPASEF analysis, this approach enabled in-depth proteome coverage, identifying over 6,300 proteins and confirmed decreased expression of the CRBN neosubstrates IKZF1, IKZF3 and RAB28 following pomalidomide treatment. Overall, the optimized workflow offers a robust, scalable and automated approach for integrated multi-omics studies, enabling efficient and reproducible proteomic profiling from limited sample inputs.
Metastatic castration-resistant prostate cancer remains an incurable disease despite the availability of novel therapeutic options and is associated with limited survival. The lack of reliable prognostic and predictive biomarkers continues to limit the implementation of personalized treatment strategies. Currently, prostate-specific antigen is the main circulating biomarker used in clinical practice; however, its ability to accurately monitor disease progression and predict outcomes is limited. This study aimed to identify circulating protein biomarkers with prognostic and predictive value to improve patient stratification and support therapeutic decision-making. Plasma samples from 48 independent patients with mCRPC were analyzed by liquid chromatography–tandem mass spectrometry. Associations between protein abundance and clinical variables were evaluated using MaAsLin2. Candidate selection for circulating tumor cell (CTC) and androgen receptor splice variant 7 (AR-V7) status was further refined using sparse partial least squares discriminant analysis (sPLS-DA) with repeated stratified five-fold cross-validation, balanced error rate optimization, and feature-selection stability assessment. Discriminative performance was evaluated by receiver operating characteristic (ROC) analysis with internal bootstrap validation. Selected proteins were also compared with baseline PSA, and survival associations were assessed using Kaplan–Meier analysis and univariable and multivariable Cox proportional hazards models adjusted for treatment line, baseline PSA, and age. Nine candidate plasma proteins were identified. HP, SERPINA3, LRG1, and ITIH3 were associated with CTC status, whereas ENO1, HSP90AA1, S100A9, SPP1, and VCL were associated with AR-V7 status. Several proteins exhibited high discrimination of the corresponding clinical phenotype, and endpoint-specific multiprotein models demonstrated strong discriminatory performance and were significantly associated with overall survival. Direct comparison with baseline PSA suggested a complementary contribution of the proteomic panels, particularly for CTC status. Survival analyses further supported the prognostic relevance of the identified proteins. This study identified nine circulating proteins with clinical relevance in metastatic castration-resistant prostate cancer and showed that their combination into compact endpoint-specific panels may provide novel and important information to clinical practice. These biomarkers may improve patient stratification, facilitate treatment selection, and enhance disease monitoring through a minimally invasive liquid biopsy approach.
Carotid artery dissection (CaAD) is a significant cause of ischaemic stroke in young adults, accounting for up to 5